Protalix Biotherapeutics Inc V.PLX.H

Primary Symbol: PLX

Healthcare Biotechnology

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of severe gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its product, Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase)- a chemically modified enzyme under development for the potential treatment of severe gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate.

NYSEAM:PLX - Post by User

Protalix Biotherapeutics Inc > Another acquisition, more stakeholder dilution......

<< Previous

Bullboard Posts

Next >>

Comment by mike49on Jul 01, 2018 1:31am

202 Views

Post# 28256758

RE:Another acquisition, more stakeholder dilution......

There is no "quality management"
These are guys who work 3rd tier,and for a reason.
Maybe,some day.not now.this is still about buying junk for 1 cent on the buck and thinking you got a deal.it is worth that much because it is worth that much.gotta help the buddies out tho.
If a deal is ever signed with tidewater,buy.
To each their own.

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal